NasdaqCM:CORTPharmaceuticals
Why Corcept Therapeutics (CORT) Is Up 8.4% After Mixed Q3 Results And Insider Share Sale
In the past few days, Corcept Therapeutics reported third-quarter 2025 earnings per share of US$0.16, surpassing analyst expectations even as revenue fell short, and CEO Joseph K. Belanoff sold 40,000 shares under a pre-arranged trading plan.
Analyst H.C. Wainwright reaffirmed a positive view on Corcept, emphasizing longer-term growth potential despite current commercial headwinds for flagship drug Korlym, which contrasts with the mixed quarterly revenue outcome.
With earnings beating...